Pancreatic Cancer Research

ResearcherShanghai Medical College of Fudan UniversityActive in the last 2 years

Weidong Shi

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-9189-9140; OpenAlex author ID A5114686222. Sources: OpenAlex.

Their work

Papers
11
Trials
0
Grants
0
Labs led
0
Collaborators
37
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: 2 papers · 2014: none · 2015: none · 2016: 3 papers · 2017: none · 2018: none · 2019: 1 paper · 2020: none · 2021: 3 papers · 2022: none · 2023: none · 2024: none · 2025: 1 paper

Papers 11

  1. Qingyihuaji formula reprograms metabolism to suppress pancreatic cancer growth and progression through LINC00346-OMA1-ATF4 signaling. Co-author DOI 10.1016/j.jep.2025.119893↗
  2. Fam83D promotes tumorigenesis and gemcitabine resistance of pancreatic adenocarcinoma through the Wnt/β-catenin pathway. Co-author DOI 10.1016/j.lfs.2021.119205↗
  3. CMTM8 as an LPA1-associated partner mediates lysophosphatidic acid-induced pancreatic cancer metastasis. Co-author DOI 10.21037/atm-20-1013↗
  4. NUCB1 Suppresses Growth and Shows Additive Effects With Gemcitabine in Pancreatic Ductal Adenocarcinoma via the Unfolded Protein Response. Co-author DOI 10.3389/fcell.2021.641836↗
  5. Long non-coding RNA LINC00346 promotes pancreatic cancer growth and gemcitabine resistance by sponging miR-188-3p to derepress BRD4 expression. Co-author DOI 10.1186/s13046-019-1055-9↗
  6. Cyr61-positive cancer stem-like cells enhances distal metastases of pancreatic cancer. Co-author DOI 10.18632/oncotarget.12248↗
  7. Is chronic hepatitis B infection a protective factor for the progression of advanced pancreatic ductal adenocarcinoma? An analysis from a large multicenter coh… Co-author DOI 10.18632/oncotarget.13000↗
  8. A retrospective analysis of survival factors of high intensity focused ultrasound (HIFU) treatment for unresectable pancreatic cancer. Co-author PMID 27448780↗
  9. A binuclear complex constituted by diethyldithiocarbamate and copper(I) functions as a proteasome activity inhibitor in pancreatic cancer cultures and xenograf… Co-author DOI 10.1016/j.taap.2013.09.009↗
  10. High intensity focused ultrasound treatment for patients with local advanced pancreatic cancer. Co-author DOI 10.5754/hge13498↗
  11. Proteome analysis of human pancreatic cancer cell lines with highly liver metastatic potential by antibody microarray. Co-author DOI 10.1007/s11010-010-0619-y↗

Closest collaborators

The 25 strongest of 37 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Zhouyu Ning · 6 shared papers, 2016–2021 · strength 0.62
  2. Yongqiang Hua · 5 shared papers, 2016–2021 · strength 0.57
  3. Zhen Chen · 6 shared papers, 2011–2021 · strength 0.41
  4. Luming Liu · 4 shared papers, 2013–2021 · strength 0.36
  5. Chenyue Zhang · 4 shared papers, 2016–2021 · strength 0.34
  6. Wei Chen · 1 shared paper, 2025 · strength 0.30
  7. Ke Zhang · 2 shared papers, 2021 · strength 0.30
  8. Lianyu Chen · 3 shared papers, 2016–2021 · strength 0.27
  9. Zhiqiang Meng · 4 shared papers, 2011–2019 · strength 0.24
  10. Luming Liu · 3 shared papers, 2011–2021 · strength 0.22
  11. Ye Li · 1 shared paper, 2021 · strength 0.15
  12. Ye Li · 1 shared paper, 2021 · strength 0.15
  13. Luming Liu · 1 shared paper, 2021 · strength 0.13
  14. Zhiqiang Meng · 1 shared paper, 2021 · strength 0.13
  15. Zhi Qiang Meng · 2 shared papers, 2013–2016 · strength 0.09
  16. Kun Wang · 2 shared papers, 2013–2016 · strength 0.09
  17. Hao Hui Chen · 1 shared paper, 2016 · strength 0.07
  18. Liping Zhuang · 1 shared paper, 2016 · strength 0.05
  19. Chien‐shan Cheng · 1 shared paper, 2016 · strength 0.05
  20. Jing Xie · 1 shared paper, 2016 · strength 0.05
  21. Peng Wang · 1 shared paper, 2016 · strength 0.05
  22. Yong-Qiang Hua · 1 shared paper, 2013 · strength 0.04
  23. Jinbin Han · 1 shared paper, 2013 · strength 0.04
  24. Yehua Shen · 1 shared paper, 2016 · strength 0.04
  25. Lei Wang · 1 shared paper, 2016 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.